Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

NEW YORK, Oct. 1 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

Intra-Cellular Therapies presented preclinical data at the 2nd World Parkinson Congress held in Glasgow, Scotland, demonstrating ITI-002 was effective in improving motor and non-motor behaviors relevant to the treatment of Parkinson's disease. In well-established pre-clinical models of PD, ITI-002 was shown to restore normal motor function when given in combination with L-DOPA; ITI-002 increased the effectiveness of a sub-threshold and a sub-maximal dose of L-DOPA when the compounds were co-administered in unilaterally 6-hydroxy dopamine-lesioned or reserpine-treated mice. This combination resulted in a full restoration of the affected limb use and a re-establishment of normal mobility. ITI-002 also reversed the akinesia and catalepsy induced by the dopamine receptor antagonist haloperidol. In other pre-clinical models, ITI-002 was shown to improve cognitive performance and to increase daytime wakefulness without causing psychomotor stimulation.

"We are pleased to have demonstrated the ability of ITI-002 to improve motor and non-motor behaviors in pre-clinical models relevant to Parkinson's disease. These data suggest ITI-002 may be useful in prolonging the effectiveness and lowering the doses of dopamine replacement therapies, thereby providing for full restoration of motor function without causing troubling side effects in patients with Parkinson's Disease," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies.  "Since ITI-002 acts by enhancing intra-cellular dopamine signaling, ITI-002 also may be useful as a stand-alone treatment early in this disease when residual dopamine is still present.  In addition, patients with Parkinson's disease often suffer co-mor
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
(Date:12/17/2014)... Md. , Dec. 17, 2014  United Therapeutics ... senior executive promotions as well as changes to ... Senior Executive Promotions United Therapeutics announced ... President and Co-Chief Executive Officer and David Zaccardelli ... Officer.  In connection with these promotions, Dr. Rothblatt,s title ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... , GENEVA, Sept. 11 Friendly LRL Holdings ... tender offer to acquire all of the outstanding shares of ... ("Startech"), effective immediately. FLH,s offer was scheduled to expire ... 30, 2009. All shares previously tendered pursuant to the ...
... , , NEW YORK, Sept. 10 ... Executive Officer Dr. Allan E. Rubenstein will be presenting at two ... will take place on September 11th, 2009 at 11:40am as part ... York, New York. The second presentation will take place on ...
... , WALTHAM, Mass. and CLEARWATER, Fla., ... Corporation, a leading developer of whole blood analyzers, and ... supplies, today announced that they have reached a definitive ... Sanvita CBGM, LLC, will acquire certain assets of Sanvita, ...
Cached Biology Technology:Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 2Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 3NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009 2Nova Biomedical and CCS Medical Reach Definitive Agreement for a Subsidiary of Nova Biomedical to Acquire Assets of CCS Medical's Subsidiary, Sanvita Inc. 2Nova Biomedical and CCS Medical Reach Definitive Agreement for a Subsidiary of Nova Biomedical to Acquire Assets of CCS Medical's Subsidiary, Sanvita Inc. 3
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Iowa Antiviral drugs block influenza A viruses from reproducing ... channel necessary for the virus to infect healthy cells, according ... Hong and published in the Feb. 4 issue of the ... Corbett Professor of Chemistry and an associate scientist for the ...
... N.J. , Feb. 3 Zymes LLC is pleased to ... be sampled at the NFL Alumni,s Super Bowl XLIV Weekend events on ... of OmegaChill at Super Bowl XLIV Weekend events along with ... health will serve as keynotes to Zymes LLC,s launch of OmegaChill ...
... Researchers at North Carolina State University have developed a "smart ... and ward off infection. When patients have hip, knee ... their bodies reject the implant. But the smart coating developed ... into the implant. The coating creates a crystalline layer next ...
Cached Biology News:Iowa State, Ames Lab chemists discover how antiviral drugs bind to and block flu virus 2Zymes LLC's Omega-3 Enhanced Water OmegaChill to be Distributed at NFL Alumni Super Bowl XLIV Weekend Events on February 5-7th, 2010 2Smart coating opens door to safer hip, knee and dental implants 2
Human IL-19 MAb (Clone 152112)...
SRY (sex determining region Y)-box 10...
... Stainless Steel Staining tray 19 x ... gel staining and blot processing.Automated staining of ... and nucleic acid analysis. Prepares blots for ... Programmable control of protocol, solution, volume, and ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
Biology Products: